
Dapinder Singh
Examiner (ID: 7865, Phone: (571)270-1774 , Office: P/3748 )
| Most Active Art Unit | 3746 |
| Art Unit(s) | 3746, 3748 |
| Total Applications | 1196 |
| Issued Applications | 994 |
| Pending Applications | 73 |
| Abandoned Applications | 157 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17889771
[patent_doc_number] => 11452718
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Aerosol pirfenidone and pyridone analog compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/922958
[patent_app_country] => US
[patent_app_date] => 2020-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 98078
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922958
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/922958 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | Jul 6, 2020 | Issued |
Array
(
[id] => 17945683
[patent_doc_number] => 20220332700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/620944
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11584
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 348
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620944
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/620944 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Jun 23, 2020 | Pending |
Array
(
[id] => 17837713
[patent_doc_number] => 20220275018
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => NOVEL SPIROBICYCLIC INTERMEDIATES
[patent_app_type] => utility
[patent_app_number] => 17/616248
[patent_app_country] => US
[patent_app_date] => 2020-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | Jun 10, 2020 | Pending |
Array
(
[id] => 16727821
[patent_doc_number] => 20210094968
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 16/869879
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869879
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869879 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | May 7, 2020 | Abandoned |
Array
(
[id] => 16252207
[patent_doc_number] => 20200261581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => INJECTABLE IBUPROFEN FORMULATION
[patent_app_type] => utility
[patent_app_number] => 16/869277
[patent_app_country] => US
[patent_app_date] => 2020-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869277 | Injectable ibuprofen formulation | May 6, 2020 | Issued |
Array
(
[id] => 17851830
[patent_doc_number] => 20220281872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => EZH2 INHIBITOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/608950
[patent_app_country] => US
[patent_app_date] => 2020-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7033
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608950
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/608950 | EZH2 inhibitor and use thereof | May 6, 2020 | Issued |
Array
(
[id] => 17687659
[patent_doc_number] => 20220194951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG
[patent_app_type] => utility
[patent_app_number] => 17/605456
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15096
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605456
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605456 | DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG | Apr 28, 2020 | Abandoned |
Array
(
[id] => 16221192
[patent_doc_number] => 20200246308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B FOR IMPROVING COGNITIVE CAPACITY OR COGNITIVE FUNCTION
[patent_app_type] => utility
[patent_app_number] => 16/856624
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15532
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856624
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/856624 | SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B FOR IMPROVING COGNITIVE CAPACITY OR COGNITIVE FUNCTION | Apr 22, 2020 | Abandoned |
Array
(
[id] => 16222682
[patent_doc_number] => 20200247798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => THERAPEUTIC AGENT FOR ANXIETY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/853885
[patent_app_country] => US
[patent_app_date] => 2020-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16853885
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/853885 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Apr 20, 2020 | Abandoned |
Array
(
[id] => 17684893
[patent_doc_number] => 20220192185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => STABILIZATION OF SUSPENSION CONCENTRATES BY HIGHLY SULFONATED LIGNOSULFONATE
[patent_app_type] => utility
[patent_app_number] => 17/602910
[patent_app_country] => US
[patent_app_date] => 2020-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602910
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602910 | STABILIZATION OF SUSPENSION CONCENTRATES BY HIGHLY SULFONATED LIGNOSULFONATE | Apr 19, 2020 | Abandoned |
Array
(
[id] => 17685775
[patent_doc_number] => 20220193067
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA
[patent_app_type] => utility
[patent_app_number] => 17/603886
[patent_app_country] => US
[patent_app_date] => 2020-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Apr 19, 2020 | Pending |
Array
(
[id] => 17720362
[patent_doc_number] => 20220213082
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => PRODRUG OF CASPASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/603386
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5785
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/603386 | PRODRUG OF CASPASE INHIBITOR | Apr 16, 2020 | Abandoned |
Array
(
[id] => 17655228
[patent_doc_number] => 20220175693
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => DIETARY SUPPLEMENT COMPRISING LUTEIN FOR TELOMERE PROTECTION, AND METHOD FOR PRODUCTION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/603348
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9756
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/603348 | DIETARY SUPPLEMENT COMPRISING LUTEIN FOR TELOMERE PROTECTION, AND METHOD FOR PRODUCTION THEREOF | Apr 14, 2020 | Pending |
Array
(
[id] => 17704471
[patent_doc_number] => 20220204477
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => BENZIMIDAZOLE DERIVATIVES AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/602028
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12666
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602028 | Benzimidazole derivatives and their uses | Apr 9, 2020 | Issued |
Array
(
[id] => 17830005
[patent_doc_number] => 20220267309
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/605828
[patent_app_country] => US
[patent_app_date] => 2020-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10593
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 551
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605828
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605828 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | Apr 8, 2020 | Abandoned |
Array
(
[id] => 16686691
[patent_doc_number] => 20210069166
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => Combination Therapy
[patent_app_type] => utility
[patent_app_number] => 16/833819
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833819
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833819 | Combination Therapy | Mar 29, 2020 | Abandoned |
Array
(
[id] => 17641860
[patent_doc_number] => 20220169598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/593877
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -71
[patent_words_short_claim] => 183
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/593877 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | Mar 26, 2020 | Abandoned |
Array
(
[id] => 17859740
[patent_doc_number] => 11440885
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Substituted 1-arylalkyl-4-acylaminopiperidine compounds and methods of producing and using the same
[patent_app_type] => utility
[patent_app_number] => 16/829299
[patent_app_country] => US
[patent_app_date] => 2020-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11842
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16829299
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/829299 | Substituted 1-arylalkyl-4-acylaminopiperidine compounds and methods of producing and using the same | Mar 24, 2020 | Issued |
Array
(
[id] => 17640524
[patent_doc_number] => 20220168262
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => AMPHIPHILIC PLATINUM (IV) PRODRUG AND CANCER TREATMENT PROCESS
[patent_app_type] => utility
[patent_app_number] => 17/593472
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593472
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/593472 | AMPHIPHILIC PLATINUM (IV) PRODRUG AND CANCER TREATMENT PROCESS | Mar 16, 2020 | Pending |
Array
(
[id] => 17609749
[patent_doc_number] => 20220152028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/438452
[patent_app_country] => US
[patent_app_date] => 2020-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438452
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/438452 | COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUS | Mar 11, 2020 | Abandoned |